BioSpace News Archive

bluebird bio, Inc. announced that new data from the clinical development program for its investigational elivaldogene autotemcel gene therapy in patients with cerebral adrenoleukodystrophy, including data from the Phase 2/3 Starbeam study and available data from the Phase 3 ALD-104 study

CytoSorbents Corporation has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb® under its FDA Emergency Use Authorization in adult, critically-ill, COVID-19 patients with imminent or confirmed respiratory failure.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex

Achieves analytical performance for detecting active 3C-protease in a rapid visual format Initiates multicenter clinical trial at Assuta Ashdod Hospital and Tel Aviv University in Israel Technology opens potential for self-administered tests at home, school, work and airports

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that it has notified the U.S. Food and Drug Administration (FDA) of the intent to commercially distribute the eSensor® SARS-CoV-2 Test for clinical use.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F. Oliviero, President and Chief Executive Officer, will present a company overview and participate in a panel discussion at the Fortress Biotech Virtual Summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., on Wednesday, August 19, 2020 at 1:50 p.m. ET. A registration link and webcast information can

The Evanston Group, a life sciences consulting firm that provides program and project leadership, subject matter expertise, and executive consulting and advisory services to clients in the pharmaceuticals & biologics and medical devices industries, announced today its rebrand, which includes a new logo and website (evanstongroup.com).

- MAU868 has the potential to be the first therapeutic to prevent and treat BKV-associated diseases in transplant patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA).

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced the appointment of Daniel Messina , an experienced and well regarded health services executive and entrepreneur, to its Board of Directors, effective Au